ABSTRACT Prostate cancer remains the second most commonly diagnosed cancer among the male population worldwide. Vitamin D deficiency has been linked to prostate cancer and its aggressiveness. Herein, we initiated a retrospective study to evaluate vitamin D status and monitoring in veterans with prostate cancer, and to examine the potential link between vitamin D and survival status and length of survival in this population. We found that veterans who were initially vitamin D deficient were significantly less likely to survive than those who were not initially deficient, and that both initial and follow-up vitamin D deficiency were associated with decreased likelihood of survival after prostate cancer diagnosis. We recommend that vitamin D deficiency be replaced in veterans with prostate cancer.
INTRODUCTION
Prostate cancer remains the second most commonly diagnosed cancer among the male population worldwide. In the United States, the estimated cost of prostate cancer screening was calculated to be as high as $1.86 billion per year if 50 million men aged 40 to 74 years were to undergo screening. 1 Crawford et al 2 estimated that the average 2-year cost for watchful waiting of prostate cancer was $24,809 and for active treatment over the same period was $59,286.
Older age, race, family history, obesity, physical activity, smoking, antioxidants, vitamin D, and calcium have been linked to the incidence of prostate cancer and its aggressiveness. 3 The theory that vitamin D could have anticancer benefits was suggested from epidemiological studies. However, there has been a great deal of controversy surrounding the protective role of vitamin D in prostate cancer based on small studies.
Previous studies determined that vitamin D deficiency is prevalent in veterans, but monitoring and treatment of this deficiency remains suboptimal. 4 Vitamin D deficiency may have a role in cancer survival rates in both AfricanAmericans and white Americans after consideration of other risk factors such as socioeconomic status, cancer stage at time of diagnosis and treatment. 5 Deficiency also appears closely related to increased health care costs. [6] [7] [8] [9] Peiris et al 10 
MATERIALS AND METHODS
This study was conducted at a Veterans Administration facility. The Research and Development committee at the Veterans Affairs (VA) Medical Center as well as the institutional review board at the affiliated university approved procedures and protocol. Patient data from the six VA Medical Centers in VISN 9 (Southeastern United States) between October 1, 1999 and April 30, 2012 were extracted from the electronic health records and included in the present study.
Initial and subsequent vitamin D levels were extracted and analyzed. Serum 25(OH)D concentration was determined by immunochemiluminometric assay (LabCorp, Burlington, NC), and vitamin D status was examined as a dichotomous variable with deficiency classified as 25(OH)D 20 ng/mL.
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Also extracted were 5-year survival status and days to death (for nonsurvivors). Finally, several background and medical variables were considered: age, race, body mass index (BMI), tobacco use, and latitude of residence.
Descriptive analysis was used to describe the study sample. Data analysis examining the association between vitamin D status variables (deficiency and monitoring) and survival utilized c 2 -analysis, although examination of status against days to death involved t tests. The association between number of vitamin D tests and survival was examined with a correlation coefficient, although the link between number of tests and survival status was examined with a t test. Follow-up testing controlled for background and medical variables that were significantly associated with patient outlook outcomes (age, race, BMI, tobacco use, and latitude of residence), and used logistic regression analysis.
RESULTS
During the study target period, there were 24,050 patients with a prostate cancer diagnosis. For those who did not survive, the average time to death was 3.5 years (standard deviation = 1.5 years), meaning that if a patient was going to die, he had a 66% chance of dying within 5 years. Thus, the sample was restricted to males who had been diagnosed at least 5 years ago (before April 30, 2007 ) to accurately examine survival as an outcome. This reduced the sample to 16,535 patients.
Characteristics of the sample are presented in Table I . The average participant was in his 70s, Caucasian, and overweight. Over one quarter of participants used tobacco. Vitamin D testing was not common in this sample, with fewer than one in five prostate cancer patients ever tested, and only just over half of those receiving any follow-up testing. Of those tested, over one third were initially deficient, with only one in five deficient at follow-up. Indeed, vitamin D level increased significantly from initial testing to first follow-up test (24.7 vs. 30.5, t = 15.9, p 0.001) for those tested more than once. Finally, nearly three quarters of patients survived to 5 years after diagnosis. Of those who did not survive, length of survival was well over 2 years.
First examined was whether vitamin D deficiency status predicted outlook in prostate cancer patients. Vitamin D status in relation to outlook (both survival and days to death) was examined for both initial vitamin D status and vitamin D status at first follow-up test (Table II) . As can be seen, those who were initially vitamin D deficient were significantly less likely to survive than those who were not initially deficient, but among those who did not survive, initial vitamin D status was unrelated to length of survival. Similarly, follow-up vitamin D status also predicted survival status, but not length of survival.
Controlled analyses were run for the significant associations predicting survival from initial and follow-up vitamin D status. These results are presented in Table III . As can be seen, even after control for potentially confounding background factors, both initial and follow-up vitamin D deficiency levels were associated with decreased likelihood of survival after prostate cancer diagnosis.
DISCUSSION
To the best of our knowledge, this is the first published report indicating that vitamin D status and monitoring are 12 In addition, laboratory studies at Stanford University confirmed that 1,25-dihydroxyvitamin D (calcitriol) promotes growth inhibition and differentiation in prostate cancer cells. 13 They found evidence that calcitriol reduces levels of biologically active prostaglandins in prostate cancer cells, thereby decreasing the proliferative stimulus of prostaglandins. It has also been proposed that calcitriol blocks STAT3, 14 which has several roles in the development of prostate cancer including promotion of metastasis. 15 The association of low vitamin D levels with risk of prostate cancer has remained controversial. Some previous studies suggested no association between vitamin D circulating levels and prostate cancer incidence, [16] [17] [18] although Nordic studies linked vitamin D levels with prostate cancer risk, showing that both low (19 nmol/L) and high (80 nmol/L) levels of vitamin D are associated with higher prostate cancer risk. 19 However, emerging studies, like the current one, suggest an inverse correlation between vitamin D levels and progression of prostate cancer. It has been recently reported that low serum levels of 25(OH)D (lower than 20 ng/mL) strongly correlate with death from prostate cancer, 20 and vitamin D 3 supplementation (4,000 IU/day) showed a decrease in the number of positive core biopsies or decrease in Gleason score in patients with prostate cancer. 21 It was also demonstrated that vitamin D deficiency promotes prostate cancer tumor growth in bone in a murine model. 22 Small clinical studies revealed prolongation of serum prostatespecific antigen doubling time in patients with prostate cancer who received 2,000 IU of vitamin D 3 per day. 23 Analogs of calcitriol, supraphysiological daily doses (2-2.5 lg/day) of calcitriol or calcitriol in combination therapy with other drugs in patients with prostate cancer mostly revealed slowing of prostate cancer progression, reduction of the elevated serum parathyroid hormone levels but at the expense of hypercalcemia and renal stone formation. 24 Our study findings are consistent with the above-mentioned research, showing that veterans with prostate cancer that were not vitamin D deficient were significantly more likely to survive than those that were not, suggesting an important role of vitamin D in patients with prostate cancer. It has been reported previously that prognosis for internal cancers, including prostate cancer, is best for cases diagnosed in the seasons with adequate vitamin D status. 25, 26 Additional studies have also found an association between low plasma 25(OH)D and CYP27A1 and VDR (genes involved in vitamin D metabolism and signaling) with advanced-stage and lethal prostate cancer. 12, 27 Genetic variations in vitamin D pathway genes (VDR, CYP27B1, and CYP24A1) alter both risk of recurrence/ progression and prostate cancer-specific mortality. 28 However, seasonally no overall statistically significant variation in mRNA expression of six vitamin D genes or VDR protein levels has been found. 29 Among those veterans who did not survive, those with vitamin D tested survived significantly longer than those who did not have testing. Vitamin D testing remained a significant risk factor for adverse outcomes after adjusting for age, BMI, tobacco use, and latitude, also predicting time to death. Interestingly, among those who did not survive, initial vitamin D status was unrelated to length of survival. Similarly, follow-up vitamin D status also predicted survival status, but not length of survival. This suggests that it is perhaps important to replete these patients with vitamin D at the time of diagnosis or, preferably, earlier. Improvement of the survival status and longevity might be less effective if attempts to address vitamin D status are made after the onset of prostate cancer.
This study has several limitations because of its retrospective nature. Since this study was correlational, no definitive conclusions can be made regarding a potential causal link between vitamin D status and monitoring, and prostate cancer outcomes. However, findings support other published reports that have shown in prospective studies that increases in vitamin D levels predict better prostate cancer outcomes, even in the absence of other improvements in diet or health. 3, 18 In addition, management of vitamin D status in the private sector for some veterans could not be factored into our analysis as these data were unavailable. Finally, it is also possible that we studied a less aggressive form of prostate cancer than is typical, and findings may only apply to specific subsets of patients with prostate cancer.
CONCLUSIONS
There are several compelling reasons for testing and treating prostate cancer patients with vitamin D, pending large-scale prospective studies. Indeed, another study found that treating patients with both metastatic prostate cancer and vitamin D deficiency with 2,000 IU/day of vitamin D improved bone pain and muscle strength. 30 Antiandrogen therapy, which is often used to treat prostate cancer, is associated with osteoporosis (which is strongly linked to vitamin D deficiency), and studies have revealed inadequate evaluation and treatment for osteoporosis in such patients. 31 Given these considerations and the potential to improve prostate cancer outcomes at minimal cost, we recommend that all prostate cancer patients be prescribed 2,000 IU vitamin D 3 daily, with this dose appropriately adjusted based on sequential monitoring.
